drugset / Trial / NCT06447623
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer. The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy.
Timeline
- Start
- 2024-06-11
- Primary completion
- 2027-02-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | — | — |
| Background | Anastrozole | Other / unclassified | — | — |
| Background | Dalpiciclib | Small molecule | — | — |
| Background | Exemestane | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Letrozole | Other / unclassified | — | — |